1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO, M0
Provides an Update Regarding Jury Verdict in AMITIZA® (Lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results
Earnings Report (Kessan Tanshin) for the Fiscal Year Ended March 31, 2026
Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Management in Japan in 2026
Zasocitinib IR Event Phase 3 Psoriasis Data Presented at AAD March 28th, 2026 ET / March 29th, 2026 JST
Announces Candidates for Board of Directors and Change in Representative Director at Upcoming Shareholders Meeting
Announces Next Steps in Its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook
Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Annual and Transition Report of Foreign Private Issuers
Prospectus Filed Pursuant to Rule 424(b)(2)
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Certificate
No filings found
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Specialized Disclosure Report